Imunon’s (IMNN) “Buy” Rating Reaffirmed at D. Boral Capital

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a note issued to investors on Friday,Benzinga reports. They currently have a $29.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Imunon in a research note on Thursday, December 19th.

Imunon Trading Up 7.6 %

IMNN stock opened at $0.96 on Friday. The stock has a market cap of $13.88 million, a P/E ratio of -0.51 and a beta of 2.04. Imunon has a twelve month low of $0.48 and a twelve month high of $3.65. The company’s 50 day moving average is $0.85 and its two-hundred day moving average is $1.03.

Imunon (NASDAQ:IMNN) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. During the same quarter last year, the business earned ($0.37) EPS. On average, equities research analysts predict that Imunon will post -1.68 earnings per share for the current year.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.